EZH2 and melanoma: Given the high coexistence rate (29%) of EZH2 gain and BRAF V600E mutation in our cohort, we for the first time evaluated the efficacy of combination therapy with EZH2 and BRAF inhibitors in melanoma cell lines and PDX mouse models.